Spectroscopic analyser

• US 9,581,552 B2
• Filed: 04/10/2012
• Issued: 02/28/2017
• Est. Priority Date: 04/06/2011
• Status: Active Grant

• Current Assignee: Klein Medical Ltd.
• Original Assignee: Klein Medical Ltd.
• Inventors: Krouse, Donal Paul, Simpkin, Raymond Andrew, Smith, Bryan James
• Primary Examiner(s): Porta, David
• Assistant Examiner(s): RIDDICK, BLAKE CUTLER
• Application Number:
  US14/110,134
• Publication Number:
  US 20140246591A1
• Time in Patent Office: 1,785 Days
• Field of Search: 250/339.07, 250/339.12, 250/339.08, 250/339.09, 356/301
• US Class Current: 1/1
• CPC Class Codes: G01J 2003/1286 Polychromator in general
• CPC Class Codes: G01J 3/10 Arrangements of light sources specially adapted for spectrometry or colorimetry
• CPC Class Codes: G01J 3/28 Investigating the spectrum using colour filters G01J3/51
• CPC Class Codes: G01J 3/42 Absorption spectrometry; Double beam spectrometry; Flicker spectrometry; Reflection spectrometry beam switching arrangements G01J3/08
• CPC Class Codes: G01N 2021/3595 using FTIR
• CPC Class Codes: G01N 21/3577 for analysing liquids, e.g. polluted water
• CPC Class Codes: G01N 21/359 using near infrared light
• CPC Class Codes: G01N 21/84 Systems specially adapted for particular applications
• CPC Class Codes: G01N 2201/0612 Laser diodes
• CPC Class Codes: G01N 2201/0691 Modulated (not pulsed supply)

Abstract

An analyzer 10 for identifying or verifying or otherwise characterizing a liquid based drug sample 16 comprising: an electromagnetic radiation source 11 for emitting electromagnetic radiation 14a in at least one beam at a sample 16, the electromagnetic radiation comprising at least two different wavelengths, a sample detector 17 that detects affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the sample, and a processor 18 for identifying or verifying the sample from the detected affected electromagnetic radiation, wherein each wavelength or at least two of the wavelengths is between substantially 1300 nm and 2000 nm, and each wavelength or at least two of the wavelengths is in the vicinity of the wavelength(s) of (or within a region spanning) a spectral characteristic in the liquid spectrum between substantially 1300 nm and 2000 nm.

Claims

1. An analyser for identifying or verifying a liquid drug sample for delivery to a patient to reduce risk of adverse drug events comprising:

an electromagnetic radiation source for emitting electromagnetic radiation in at least one beam at a liquid drug, the liquid drug comprising a drug in a base liquid, the liquid drug having a liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between substantially 1300 nm and 2000 nm, the electromagnetic radiation comprising at least two different wavelengths between substantially 1300 nm and 2000 nm, each wavelength being selected to be in the vicinity of or within a region spanning a wavelength of a spectral characteristic feature of the base liquid spectrum,

a liquid drug detector that detects affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the liquid drug, the detected affected electromagnetic radiation being indicative of spectral information of the liquid drug at the wavelengths, the liquid drug detector providing output representing the spectral information of the liquid drug at the wavelengths, and

a processor configured to;

query a database of reference liquid drugs and spectral information of the reference liquid drugs at the wavelengths, each reference liquid drug comprising a drug in a base liquid, the reference liquid drug having a reference liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between substantially 1300 nm and 2000 nm, the spectral information of each reference liquid drug relating to the liquid drug spectrum of the reference drug at the wavelengths such that the spectral information of each reference liquid drug comprises a contribution from the base liquid spectrum of the reference liquid drug at the wavelengths, and

identify or verify the liquid drug using;

a) the liquid drug detector output representing the spectral information of the liquid drug, and b) the spectral information of the reference liquid drugs,

wherein for each reference liquid drug in the database, the difference between the base liquid spectrum and the liquid drug spectrum of the reference drug at the wavelengths deviates from the difference between the base liquid spectrum and the liquid drug spectrum at the wavelengths for the other reference liquid drugs in the database, the deviation providing discrimination between the respective spectral information of the respective reference liquid drugs at those wavelengths to enable the drug identification or verification of the liquid drug using the output representing the spectral information of the liquid drug.

2. An analyser according to claim 1 wherein the electromagnetic radiation comprises a plurality of electromagnetic radiation beams, each beam having a different wavelength.

3. An analyser according to claim 1 wherein the wavelengths span or capture a plurality of at least some of the spectral characteristic features in the liquid spectrum between 1300 nm and 2000 nm.

4. An analyser according to claim 1 wherein the liquid spectrum comprises two or more spectral characteristic features, and wherein:

each spectral characteristic feature falls in or spans a region of the liquid spectrum,

each wavelength falls within one of the regions.

5. An analyser according to claim 1 wherein the spectral characteristic features comprise peaks, troughs, inflections, stable points or regions plateaus, knees and/or slopes of the liquid spectrum.

6. An analyser according to claim 1 further comprising a modulator for modulating the electromagnetic radiation beam(s) emitted at the liquid drug resulting in detected affected radiation detected by the liquid drug detector that is modulated wherein the processor as part of identifying or verifying the liquid drug from the output from the detector removes the dark current component from the output representing the detected affected modulated electromagnetic radiation.

7. An analyser according to claim 1 wherein the source is a laser comprising a photodetector, wherein the photodetector detects electromagnetic radiation from the laser and outputs the reference information.

8. An analyser according to claim 1, wherein the source is a plurality of lasers in a single package, each laser configured to emit an electromagnetic radiation beam at a fixed or tuneable wavelength.

9. An analyser according to claim 1, wherein the detector and/or source are temperature compensated to provide temperature stability, using thermistors and peltier devices in a closed loop system.

10. A method for identifying or verifying a liquid drug for delivery to a patient to reduce risk of adverse drug events comprising:

emitting electromagnetic radiation in at least one beam at a liquid drug, the liquid drug comprising a drug in a base liquid, the liquid drug having a liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between substantially 1300 nm and 2000 nm, the electromagnetic radiation comprising at least two wavelengths between substantially 1300 nm and 2000 nm, each wavelength being selected to be in the vicinity of or within a region spanning a wavelength of a spectral characteristic feature of the base liquid spectrum,

detecting affected electromagnetic radiation resulting from the emitted electromagnetic radiation affected by the liquid drug, the detected affected electromagnetic radiation being indicative of spectral information of the liquid drug at the wavelengths, the liquid drug detector providing output representing the spectral information of the liquid drug at the wavelengths,

querying a database of reference liquid drugs and spectral information of the reference liquid drugs at the wavelengths, each reference liquid drug comprising a drug in a base liquid, the reference liquid drug having a reference liquid drug spectrum and the base liquid having a base liquid spectrum comprising at least one spectral characteristic feature between substantially 1300 nm and 2000 nm, the spectral information of each reference liquid drug relating to the liquid drug spectrum of the reference drug at the wavelengths such that the spectral information of each reference liquid drug comprises a contribution from the base liquid spectrum of the reference liquid drug at the wavelengths, and

identifying or verifying the liquid drug using;

a) the liquid drug output representing the spectral information of the liquid drug, and b) the spectral information of the reference liquid drugs,

wherein for each reference liquid drug in the database, the difference between the base liquid spectrum and the liquid drug spectrum of the reference drug at the wavelengths deviates from the difference between the base liquid spectrum and the liquid drug spectrum at the wavelengths for the other reference liquid drugs in the database, the deviation providing discrimination between the respective spectral information of the respective reference liquid drugs at those wavelengths to enable the identification or verification of the liquid drug using the output representing the spectral information of the liquid drug.

11. A method according to claim 10 wherein the electromagnetic radiation comprises a plurality of electromagnetic radiation beams, each beam having a different wavelength.

12. A method according to claim 10 wherein the different wavelengths span or capture a plurality of at least some of the spectral characteristic features in the liquid spectrum between 1300 nm and 2000 nm.

13. A method according to claim 10 wherein the liquid spectrum comprises two or more spectral characteristic features, and wherein:

each spectral characteristic feature falls in or spans a region of the liquid spectrum,

each wavelength falls within one of the regions.

14. A method according to claim 10 wherein the spectral characteristic features comprise peaks, troughs, inflections, stable points or regions, plateaus, knees and/or slopes of the liquid spectrum.

15. A method according to claim 10 wherein the base liquid is water and comprises spectral characteristic features falling in the following regions of the water spectrum:

a first region between 1300 nm and 1400 nm,

a second region between 1400 nm and 1500 nm,

a third region between 1500 nm and 1600 nm,

a fourth region between 1600 nm and 1700 nm,

a fifth region between 1700 nm and 1800 nm, and

a sixth region between 1800 nm and 2000 nm.

16. A method according to claim 10 wherein the electromagnetic radiation is generated using a source comprising a plurality of lasers, each laser configured to emit an electromagnetic radiation beam at a fixed or tuneable wavelength and each laser comprising a photodetector, wherein the photodetector detects electromagnetic radiation from the laser and outputs the reference information.

17. A method according to claim 10, further comprising temperature compensating to provide temperature stability of a source of the electromagnetic radiation and/or a detector detecting the affected electromagnetic radiation, using thermistors and peltier devices in a closed loop system.